SCHEMBL670076

SCHEMBL670076

CCCCC(N)CCCCO

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.52
LMNA P02545 3/20 0.50
ALDH1A1 P00352 3/20 0.50
HSD17B10 Q99714 1/20 0.50
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
TSHR P16473 1/20 0.50
S1PR2 O95136 5/20 0.48
S1PR1 P21453 5/20 0.48
S1PR3 Q99500 5/20 0.48
S1PR4 O95977 4/20 0.48
OPRM1 P35372 1/20 0.44
CYP2D6 P10635 2/20 0.43
PLA2G1B P04054 1/20 0.43
PLA2G2A P14555 1/20 0.43
SPHK1 Q9NYA1 1/20 0.43
GMNN O75496 1/20 0.43
POLB P06746 1/20 0.43
THPO P40225 1/20 0.43
MTOR P42345 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8803507 0.95 SMN1; SMN2 (0.60) SMN1; SMN2LMNAALDH1A1HSD17B10MEN1
SCHEMBL16005507 0.93 LMNA (0.62) SMN1; SMN2LMNAALDH1A1HSD17B10MEN1
SCHEMBL8587079 0.93 LMNA (0.62) SMN1; SMN2LMNAALDH1A1HSD17B10MEN1
SCHEMBL28171439 0.93 LMNA (0.62) SMN1; SMN2LMNAALDH1A1HSD17B10MEN1
SCHEMBL3480724 0.93 LMNA (0.62) SMN1; SMN2LMNAALDH1A1HSD17B10MEN1
SCHEMBL16005163 0.93 LMNA (0.62) SMN1; SMN2LMNAALDH1A1HSD17B10MEN1
SCHEMBL8584485 0.93 LMNA (0.62) SMN1; SMN2LMNAALDH1A1HSD17B10MEN1
SCHEMBL16005044 0.93 LMNA (0.62) SMN1; SMN2LMNAALDH1A1HSD17B10MEN1
SCHEMBL21919473 0.92 ALDH1A1 (0.50) SMN1; SMN2LMNAALDH1A1HSD17B10MEN1
SCHEMBL258876 0.92 ALDH1A1 (0.50) SMN1; SMN2LMNAALDH1A1HSD17B10MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220002265-A1 RHO KINASE INHIBITOR, METHOD FOR PREPARING SAME AND USES THEREOF BEIJING INCREASE INNOVATIVE DRUG CO., LTD (CN) 2022-01-06 US disclosed
EP-3878846-A1 RHO KINASE INHIBITOR, METHOD FOR PREPARING SAME AND USES THEREOF Beijing Increase Innovative Drug Co., Ltd. (CN) 2021-09-15 EP disclosed
EP-2606022-A2 NOVEL BENZOQUINONE DERIVATIVES AND USE THEREOF AS MODULATORS OF MITOCHONDRIAL FUNCTION Santhera Pharmaceuticals (Schweiz) AG (CH) 2013-06-26 EP disclosed
WO-2012022467-A2 NOVEL BENZOQUINONE DERIVATIVES AND USE THEREOF AS MODULATORS OF MITOCHONDRIAL FUNCTION SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) 2012-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220002265-A1 RHO KINASE INHIBITOR, METHOD FOR PREPARING SAME AND USES THEREOF ROCK1, RHOA, ROCK2 SMN1; SMN2 4404/4885LMNA 1555/4885ALDH1A1 4142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.